

Proteomic Profile of Epithelioid Sarcoma

Kenta Mukaihara^{1,2}, Daisuke Kubota³, Akihiko Yoshida⁴, Naofumi Asano¹, Yoshiyuki Suehara², Kazuo Kaneko², Akira Kawai³ and Tadashi Kondo^{1*}

¹Division of Pharmacoproteomics, National Cancer Center Research Institute, Tokyo, Japan

²Department of Orthopedic Surgery, Juntendo University School of Medicine, Tokyo, Japan

³Division of Musculoskeletal Oncology, National Cancer Center Hospital, Tokyo, Japan

⁴Pathology and Clinical Laboratory Division, National Cancer Center Hospital, Tokyo, Japan

Abstract

Epithelioid sarcoma (ES) is a rare soft tissue sarcoma affecting young adults. It is a slow-growing tumor with a high rate of recurrence and metastasis to lymph nodes. Although deletion of the tumor suppressor gene, *SMARCB1/INI1*, has been identified in ES, the molecular background factors are largely unknown. To clarify the molecular aberrations contributing to the malignant features of ES, we investigated the proteins present in ES tumor tissues. Two-dimensional difference gel electrophoresis of homogenized tissue samples revealed 3363 protein spots, of which 91 showed differences in intensity between tumor and adjacent non-tumor tissues in eight ES cases. Using mass spectrometry, we characterized 69 unique proteins corresponding to these protein spots. We found that the complex histology of ES was obstacle for the investigation of molecular backgrounds of ES. For instance, although the higher expression of CAPZB in tumor tissues was confirmed by Western blotting, the immunohistochemistry did not determine the specific localize CAPZB in tumor cells. Our study demonstrated the possible utility of proteomic study, and at the same time the difficult aspect of proteomics using homogenized tissue samples.

Keywords: Epithelioid sarcoma; Proteomics; 2D-DIGE

Introduction

Epithelioid sarcoma (ES) is a soft tissue sarcoma affecting young adults [1]. ES is classified into two subtypes according the pathological observations: a classic form that often arises in the classic extremities as a slow-growing nodule [2], and a proximal form that tend to arise in deep areas of the pelvis, perineum, and genital tract [3]. Although the proximal form may have a more aggressive clinical course than the classic forms [4], the clinical courses are diverse, even for identical subtypes. Previous reports have focused on clinical and pathological prognostic factors associated with ES [3,5-7]. Recently, deletion of the *SMARCB1/INI1* tumor-suppressor gene (INI1) was reported in proximal-type ES [8], and loss of its expression was observed in approximately 90% of classic and proximal ES cases [9]. The tumorigenic properties of INI1 genetic inactivation have been reported [10], and loss of INI1 protein expression in ES has been shown to be due to epigenetic mechanisms of gene silencing by specific miRNAs [11]. As well as molecular studies of INI1, a large-scale immunohistochemical study has revealed that loss of INI1 expression had no prognostic impact on ES [4]. These reports suggest that there may be a molecular basis for differences in the clinical and pathological features of ES, and that further investigations to identify these aberrations might have clinical relevance.

To investigate the molecular basis of the malignant features of ES, previous studies have employed global molecular analysis. In a global gene expression study to identify the invasive potential of ES, Weber et al. carried out differential display RT-PCR with arbitrary primers using ES cell lines differing in their invasive potential, and found that expression of apoferritin light chain, GRU-1A, cytochrome *c* oxidase I, TI-227H, and ELISC-1 was associated with differences in invasiveness [12]. Using comparative genomic hybridization, Lushnikova et al. [13] examined DNA copy number changes in ES and reported recurrent gain at 11q13, and using immunohistochemistry confirmed overexpression of the cyclin D1 gene, located in 11q13. These studies suggested that a global molecular approach was effective, and that further investigations of a similar nature were warranted in ES. However, modern technology has not yet been applied for global molecular analysis of ES.

In the present study, to clarify the molecular background of ES, we adopted a proteomics approach using primary tumor tissues of ES. Proteomics can provide unique data that cannot be obtained using other global approaches. Using two-dimensional difference gel electrophoresis (2D-DIGE) and mass spectrometry [14], we identified proteins showing differential expression between tumor tissues and surrounding non-tumor tissues obtained from the ES patients.

Materials and Methods

Patients and tumor samples

This study included 8 patients with ES who were treated at the National Cancer Center Hospital between 1993 and 2013. Tumor and adjacent non-tumor tissues were obtained at the time of surgery, and stored in liquid nitrogen until use. Table 1 summarizes the patients' clinical and pathological information. This project was approved by the ethical review board of the National Cancer Center, and signed informed consent was obtained from all of the study patients.

Protein expression profiling

Proteins were extracted from frozen tissues as described previously [14]. In brief, tumor tissues were powdered with a Multi-beads shocker (Yasui Kikai, Osaka, Japan) in the presence of liquid nitrogen, and treated with urea lysis buffer (6 M urea, 2 M thiourea, 3% CHAPS, 1% Triton X-100). After centrifugation at 15,000 rpm for 30 min, the

***Corresponding author:** Tadashi Kondo, MD, PhD, Division of Pharmacoproteomics, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan, Tel: +81-3-3542-2511; Fax: +81-3-3547-5298; E-mail: takondo@ncc.go.jp

Received May 20, 2014; Accepted June 19, 2014; Published June 24, 2014

Citation: Mukaihara K, Kubota D, Yoshida A, Asano N, Suehara Y, et al. (2014) Proteomic Profile of Epithelioid Sarcoma. J Proteomics Bioinform 7: 158-165. doi:10.4172/0974-276X.1000316

Copyright: © 2014 Mukaihara K, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

Case no.	Age	Gender	Location	Subtype	INI1 expression	Grade ^a	TNM stage ^b	Treatment	Local recurrence	Lymph node metastasis	Initial metastatic sites	Disease-free survival (months)	Overall survival (months)	Outcome
ES_1	29	F	Perineum	Classic	Negative	2	III	Curative surgery	Present	Absent	Lymph node	12	143	DOD
ES_2	52	M	Perineum	Proximal	Negative	2	IIA	Curative surgery	Present	Present	Lymph node	9	168	DOD
ES_3	36	M	Inguinal	Proximal	Negative	3	NA	Curative surgery	Present	Absent	Lung	25	113	DOD
ES_4	64	F	Back	Proximal	Positive	3	III	Curative surgery	Present	Absent	Lung	7	17	DOD
ES_5	32	M	Lower leg	Classic	Negative	3	III	Curative surgery	Absent	Absent	Lymph node	19	35	DOD
ES_6	48	F	Axilla	Proximal	Negative	3	IV	Palliative treatment	Present	NA	Lung	NA	4	DOD
ES_7	22	M	Foot	Classic	NA	2	IIA	Curative surgery	Absent	Absent	Bone	10	18	DOD
ES_8	41	M	Perineum	Classic	Negative	2	III	Curative surgery	Present	Present	Lymph node	10	19	DOD

NA: Data not available DOD: Dead of disease

^aModified FNCLCC (French Federation of Cancer Centers) system (Coindre et al. Cancer. 1986, 58: 306-309).

^bTumor-Nodes-Metastases Classification.

Table 1: Clinicopathologic features of ES samples.




Figure 1: An overview of the experimental procedure for 2D-DIGE experiments with an internal control sample. A. The internal control and the individual sample are labeled with Cy3 and Cy5, respectively, mixed together, and separated by 2D-PAGE. After electrophoresis, the gel is laser-scanned, and the Cy3 and Cy5 images are obtained. The Cy5 image data are normalized with the Cy3 image data to compensate for any gel-to-gel variation. B. A typical gel image of the Cy3-labeled internal control sample. The spot numbers correspond to those in Figure 2 and Table 2. C. System reproducibility was evaluated by running the identical sample three times, and reproducibility was evaluated using a scattergram.

supernatant was recovered as the protein sample.

Protein expression profiling was performed by 2D-DIGE as

described previously [14]. Figure 1A gives an overview of the 2D-DIGE protocol. In brief, the internal control sample was prepared by mixing together a small portion of the samples from all individuals. Five-microgram portions of the internal control sample and each individual sample were labeled with Cy3 and Cy5, respectively (CyDye DIGE Fluor saturation dye, GE Healthcare Biosciences, Uppsala, Sweden) [15,16]. The differently labeled protein samples were mixed, and then separated by two-dimensional gel electrophoresis. The first-dimension separation was achieved using Immobiline pH gradient DryStrip gels (24 cm long, pI range 3-10, GE Healthcare Biosciences) [17]. The second-dimension separation was achieved by SDS-PAGE using our original large-format electrophoresis apparatus (33-cm separation distance, Bio-craft, Tokyo, Japan) [14]. The gels were scanned using a laser scanner (Typhoon Trio, GE Healthcare Biosciences) at appropriate wavelengths for Cy3 and Cy5. For all protein spots, the Cy5 intensity was normalized against Cy3 intensity in the same gel using the ProgenesisSameSpots software package version 3 (Nonlinear Dynamics, Newcastle-upon-Tyne, UK), in order to compensate for gel-to-gel variations. All samples were examined in triplicate gels, and the mean normalized intensity value was used for comparative study.

Statistical analysis

Statistical comparisons were performed using the Expressionist software package (GeneData, Basel, Switzerland).

Protein identification by mass spectrometry

Mass spectrometric protein identification was performed as described previously [14]. In brief, 100 µg of the protein sample was labeled with Cy5, and separated by 2D-PAGE as described above. Protein spots were recovered from the gels using our original automated spot recovery device, and digested to tryptic peptides by in-gel digestion. The peptides were subjected to liquid chromatography coupled with nanoelectrospray tandem mass spectrometry (Finnigan LTQ Orbitrap mass spectrometer and LTQ linear ion trap mass spectrometer, Thermo Electron Co., San Jose, CA). The Mascot software package (version 2.2; Matrix Science, London, UK) and SWISS-PROT database (*Homo sapiens*, 471472 sequences in the Sprot-57.5.fasta file) were used for protein identification. Proteins with a Mascot score of 34 or more were considered to be positively identified.

Western blotting

Proteins were separated by SDS-PAGE and transferred to nitrocellulose membranes. Each membrane was incubated with mouse monoclonal antibody against CAPZB (1:500 dilution, Santa Cruz Biotechnology Inc, Santa Cruz, CA), and reacted with a horseradish

peroxidase-conjugated secondary antibody (1:1000 dilution, GE Healthcare Biosciences). The immunocomplex was detected using an enhanced chemiluminescence system (ECL Prime, GE Healthcare Biosciences), and the signal was monitored with a LAS-3000 laser scanner (FujiFilm, Tokyo, Japan). The membranes were then stained with 0.2% Ponceau S and 1% acetic acid (Sigma Aldrich, St. Louis, MO) [18,19], and the intensity of the protein bands was measured using the ImageQuant software package (GE Healthcare Biosciences). The intensity of individual protein bands was normalized against that of the entire lane.

Immunohistochemistry

Immunohistochemical examination was performed using formalin-fixed, paraffin-embedded tissues. In brief, paraffin sections of 4- μ m thickness was cut from the representative block for each tumor and routinely deparaffinized. For INI1 staining, the sections were exposed to 3% hydrogen peroxide for 15 min to block endogenous peroxidase activity. The preparations were autoclaved in Targeted Retrieval Solution (Dako, Glostrup, Denmark) for antigen retrieval. The primary antibody used was INI1 (25/BAF47, 1:100; BD Biosciences, Franklin Lakes, NJ). The slides were incubated for 1 h at room temperature with the primary antibody and subsequently detected by the EnVision detection system with Linker (Dako). Diaminobenzidine was used as the chromogen, and hematoxylin as the counter stain. Complete loss of nuclear reactivity in the background of the non-neoplastic internal positive controls was regarded as deficient. For CAPZB staining, the slides were autoclaved in Tris-EDTA buffer (pH 9.0) at 121°C for 30 min and incubated with a commercial monoclonal antibody against CAPZB (1:500 dilution; Santa Cruz Biotechnology Inc.). Immunostaining was carried out by the streptavidin-biotin peroxidase method using a Strept ABC Complex/horseradish peroxidase kit (DAKO, Glostrup, Denmark).

Results and Discussion

In order to develop clinical applications that can improve the outcome of patients with ES, it has been necessary to clarify the molecular basis of ES malignancy. The recent advent of global protein expression technologies has enabled comprehensive analysis of molecular aberrations in tumor cells, and a tremendous amount of data that may lead to clinical applications has been generated. However, the proteomic approaches have not been applied to ES, probably because of its relative rarity and the fact that clinical materials for basic research are in short supply.

In this study, we conducted a proteomic comparison between tumor and non-tumor tissues in ES. This is the first report of a proteomics approach to ES. Identification of proteins showing unique expression in tumor tissues is the first step toward clarifying the molecular basis of tumor biology. The differences between tumor and non-tumor tissues may include alterations that have occurred during carcinogenesis, or during cancer progression, and reflect the various features of malignancy including invasion, metastasis and resistance to therapy. Such a simple comparison of tumor tissues with normal ones may not in itself yield significant results, because the surrounding non-tumor tissues are not normal counterparts of tumor tissues in ES. However, investigation of the proteins identified may further our understanding of the molecular backgrounds of ES.

Here we employed 2D-DIGE to investigate the proteomic background of ES. 2D-DIGE is an advanced version of 2D-PAGE, which has been widely used to examine protein expression profiles

since 1975. Although 2D-PAGE has been used for protein research for an exceptionally long period, it has a number of inherent drawbacks, one of which is gel-to-gel variations. We attempted to resolve this issue using a common internal control sample in 2D-DIGE (Figure 1A), and thus successfully compensated for any gel-to-gel variations (Figure 1C). Generally, the separation performance of gel-based proteomics parallels the separation distance achieved by electrophoresis. For longer separation distance, we developed our original large-format electrophoresis apparatus, and we successfully observed 3363 protein spots using it (Figure 1B). In 2D-DIGE, proteins are detected by laser scanning of the gels sandwiched between low-fluorescence glass plates. Therefore, a gel as large as the laser scanning area can be used without any risk of breaking the fragile polyacrylamide gel. The higher separation performance may also contribute to the high reproducibility of protein expression profiling (Figure 1C). When we ran an identical sample three times independently, the intensity of at least 85.8% of 3363 protein spots observed was scattered within a difference of two-fold, and showed a relative correlation of at least 0.84. As the intensity of at least 98.8% of the 3363 protein spots was scattered within a six-fold difference range, we further examined spots that showed more than a six-fold difference in intensity between tumor and non-tumor tissues. The intensities of all 3363 protein spots are summarized in Supplementary Table 1.

We identified 91 protein spots whose intensity differed significantly ($p < 0.01$, > 6 -fold ratio of means) between tumor and non-tumor tissues. These 91 spots are localized on the 2D image shown in Figure 1B. The normalized and averaged intensity of the 91 spots is shown in the form of a heat map in Figure 2, which was created using the data in Supplementary Table 1. Mass spectrometric protein identification revealed that the 91 protein spots corresponded to 69 distinct gene products (Figure 2 and Table 2). Generally, gene products are modified after transcription and translation, and single genes can generate multiple protein forms. Thus, the molecular events that had given rise to the multiple protein forms of these 69 genes, and how they differed between tumor and non-tumor tissues, were clearly of interest. Supplementary Table 2 summarizes the supporting data used for identification of these proteins. Generally, proteome data are biased by proteomics technologies, and we observe what we can observe in given technical conditions. As only proteins with differential expression were subjected to mass spectrometric protein identification, we cannot evaluate the limitation of 2D-DIGE. However, 2D-DIGE in this study clearly has limitation. For example, only the proteins with pI ranging between 4 and 7 were included in this study, and the proteins with pI higher than 7 were not considered. Moreover, the proteins with low expression level such as transcription factors may not be included either. Indeed, we didn't identify the products of SMARCB1/INI1, whose unique expression was reported in ES. Generally, proteomics modalities also have their own technical limitations, and there is no almighty proteomics modality. Therefore, the combined use of multiple proteomics modalities is required for comprehensive protein expression study. We demonstrated the presence of proteins with differential expression between tumor and non-tumor tissues using 2D-DIGE, and we hope that our proteomic study facilitates further investigation of ES at the protein level.

Among them, we examined the differential expression of CAPZB [20], which was up-regulated in ES tumor tissues (Figure 2 and Table 2). CAPZB is a member of the F-actin capping protein family, which bind the barbed ends of actin and regulate cell morphology and cytoskeletal organization [21]. Although CAPZB has been reported in human salivary gland cancer [22], its roles in other types of cancer have not




Figure 2: Results of comparative 2D-DIGE and protein identification by mass spectrometry. The results of the protein expression study are summarized in the form of a heat map. The results of protein identification are shown on the left side of the heat map. The protein spot numbers correspond to those in Figure 1B and Table 2.

Spot no. ^a	Accession no. ^b	Symbol	Identified protein	P value	Fold difference	pI ^c (obs)	MW ^c (obs)(Da)	Protein score ^d	Peptide matches	Peptide sequence coverage (%)
790	Q07065	CKAP4	Cytoskeleton-associated protein 4	2.95E-03	6.502	5.63	66097	1007	21	38
1084	B4E102	IF4A1	Eukaryotic initiation factor 4A-I	1.86E-03	7.837	5.32	46353	68	1	2.5
1313	Q92890	UFD1	Ubiquitin fusion degradation protein 1 homolog	1.55E-04	8.600	6.27	34763	59	1	4.9
1315	Q6IBS0	TWF2	Twinfilin-2	1.55E-04	9.508	6.37	39751	593	13	36.1
1345	O15372	EIF3H	Eukaryotic translation initiation factor 3 subunit H	1.55E-04	7.070	6.09	40076	102	2	5.4
1369	P07355	ANXA2	Annexin A2	6.22E-04	6.512	7.57	38808	316	6	18.3
1393	P07910	HNRPC	Heterogeneous nuclear ribonucleoproteins C1/C2	1.55E-04	6.699	4.95	33707	192	5	15.4
1434	Q14966	ZN638	Zinc finger protein 638	1.55E-04	6.594	6.02	221914	48	1	1.2
1478	O15287	FANCG	Fanconi anemia group G protein	1.55E-04	6.917	5.32	69423	45	1	2.7
1505	G3V2C9	GBLP	Guanine nucleotide-binding protein subunit beta-2-like 1	3.11E-04	6.878	7.6	35511	508	8	30
1520	P40926	MDHM	Malate dehydrogenase, mitochondrial	2.95E-03	8.009	8.92	35937	48	1	3.3
1522	P04818	TYSY	Thymidylate synthase	6.22E-04	9.901	6.51	35978	440	9	28.1
1541	Q9HC38	GLOD4	Glyoxalase domain-containing protein 4	6.22E-04	6.622	5.4	35170	51	1	4.2
1585	P00491	PNPH	Purine nucleoside phosphorylase	1.55E-04	8.418	6.45	32325	784	20	55.4
1619	Q9H0J4	QRIC2	Glutamine-rich protein 2	1.09E-03	6.970	6.25	181228	40	1	0.5
1706	P49736	MCM2	DNA replication licensing factor MCM2	3.11E-04	6.343	5.34	102516	42	1	2.7
1746	Q9Y2X7	GIT1	ARF GTPase-activating protein GIT1	6.22E-04	8.352	6.33	85030	42	1	2.1
1760	Q8NB7	SUMF2	Sulfatase-modifying factor 2	3.11E-04	9.799	7.79	33950	83	2	8.6
1792	P25940	CO5A3	Collagen alpha-3(V) chain	1.55E-04	6.524	6.37	172631	40	1	0.9
1794	Q6Z55	ZN574	Zinc finger protein 574	1.55E-04	6.139	8.44	101175	35	1	2.1
1810	O00299	CLIC1	Chloride intracellular channel protein 1	1.55E-04	11.274	5.09	27248	296	4	20.7
1811	Q9HCI6	CLIC1	Chloride intracellular channel protein 1	1.55E-04	7.218	5.09	27248	276	4	20.7
1826	Q9UL46	PSME2	Proteasome activator complex subunit 2	1.55E-04	7.675	5.44	27515	280	5	23
1830	O00299	CLIC1	Chloride intracellular channel protein 1	1.55E-04	6.377	5.09	27248	227	3	17.4
1846	Q9HCI6	K1529	Uncharacterized protein KIAA1529	1.55E-04	6.745	5.74	192404	48	2	1.2
1869	Q9HCI7	K1529	Uncharacterized protein KIAA1529	6.22E-04	7.416	5.74	192404	46	4	1.2
1873	P62318	SMD3	Small nuclear ribonucleoprotein Sm D3	6.22E-04	6.372	10.33	14021	35	1	8.7
2180	P23528	COF1	Cofilin-1	1.09E-03	6.025	8.22	18719	293	4	37.3
2181	Q9UQ35	SRRM2	Serine/arginine repetitive matrix protein 2	1.55E-04	7.990	12.05	300179	36	1	1.1
2242	P18085	ARF4	ADP-ribosylation factor 4	1.55E-04	6.686	6.59	20612	168	3	15.6
2252	P02792	FRIL	Ferritin light chain	6.22E-04	11.458	5.51	20064	125	2	17.1
2397	C9K028	NDKA	Nucleoside diphosphate kinase A	6.22E-04	6.401	5.83	17309	447	13	64.5
2504	O15511	ARPC5	Actin-related protein 2/3 complex subunit 5	1.55E-04	6.712	5.47	16367	293	7	29.1
3334	P50579	AMPM2	Methionine aminopeptidase 2	6.99E-03	9.594	5.57	53713	36	1	3.6
3635	Q07065	CKAP4	Cytoskeleton-associated protein 4	1.55E-04	6.066	5.63	66097	1209	18	38.7
3636	P30101	PDIA3	Protein disulfide-isomerase A3	1.55E-04	6.026	5.98	57146	1312	25	46.1
3731	P0C881	R10B1	Radial spoke head 10 homolog B	1.09E-03	8.385	7.16	101255	35	1	2
3754	Q8IVM7	CM029	Uncharacterized protein C13orf29	1.09E-03	6.890	9.29	18425	39	1	11
3834	P08670	VIME	Vimentin	6.22E-04	11.877	5.06	53676	1794	41	60.3
3838	E9PB7	TBB5	Tubulin beta chain	6.22E-04	9.029	4.78	50095	301	8	13.7
3927	Q9VKI9	PO2F3	POU domain, class 2, transcription factor 3	2.95E-03	7.140	8.81	47764	36	1	3.9
3928	E9PB7	TBB5	Tubulin beta chain	6.22E-04	9.912	4.78	50095	310	7	15.3
3931	P61158	ARP3	Actin-related protein 3	3.11E-04	6.479	5.61	47797	618	12	25.6
3934	O00148	DDX39	ATP-dependent RNA helicase DDX39	1.09E-03	9.134	5.46	49611	533	10	25.1
3942	Q9Y265	RUVB1	RuvB-like 1	1.09E-03	6.908	6.02	50538	175	4	8.6
3946	E7EQ64	TRY1	Trypsin-1	6.22E-04	6.405	6.08	27111	46	1	4
3964	Q9Y265	RUVB1	RuvB-like 1	1.09E-03	6.829	6.02	50538	984	17	37.3
4026	P08670	VIME	Vimentin	2.95E-03	9.717	5.06	53676	167	3	7.9
4041	O95996	APC2	Adenomatous polyposis coli protein 2	4.66E-03	6.069	9.08	245966	36	1	0.6
4089	P52597	HNRPF	Heterogeneous nuclear ribonucleoprotein F	1.55E-04	10.688	5.38	45985	146	2	8
4091	Q8IYK8	REM2	GTP-binding protein REM 2	1.55E-04	6.024	9.19	36170	38	1	8.5
4352	B1AK85	K1529	Uncharacterized protein KIAA1529	1.55E-04	6.957	5.74	192404	44	3	1.2
4399	Q9NY93	DDX56	Probable ATP-dependent RNA helicase DDX56	1.55E-04	6.235	9.34	62007	37	1	3.8
4408	Q9UJ70	NAGK	N-acetyl-D-glucosamine kinase	1.55E-04	9.736	5.81	37694	216	4	12.8
4409	Q9UJ70	NAGK	N-acetyl-D-glucosamine kinase	1.55E-04	6.083	5.81	37694	513	8	28.5
4521	Q6P1NO	C2D1A	Coiled-coil and C2 domain-containing protein 1A	6.22E-04	7.158	8.22	104397	51	1	1.6
4524	Q6DN90	IQEC1	IQ motif and SEC7 domain-containing protein 1	1.09E-03	6.000	6.49	109103	34	1	1
4526	P00338	LDHA	L-lactate dehydrogenase A chain	6.99E-03	6.880	8.44	36950	247	4	12

4532	A6NHQ2	FBLL1	rRNA/tRNA 2--O-methyltransferase fibrillar-like protein 1	1.09E-03	8.670	10.33	34711	41	1	3.6
4533	Q14315	FLNC	Filamin-C	1.09E-03	10.240	5.68	293344	39	1	0.4
4584	P47756	CAPZB	F-actin-capping protein subunit beta	1.09E-03	6.927	5.36	31616	518	11	28.2
4586	P47756	CAPZB	F-actin-capping protein subunit beta	1.55E-04	6.478	5.36	31616	431	9	21.7
4587	Q53EZ4	CEP55	Centrosomal protein of 55 kDa	1.55E-04	9.030	6.52	54433	38	1	2.6
4652	Q969P0	IGSF8	Immunoglobulin superfamily member 8	1.55E-04	13.696	8.23	65621	35	1	1.6
4661	Q8WZ26	YS006	Putative uncharacterized protein PP6455	1.55E-04	6.794	8.26	15165	35	1	6.7
4680	Q8NB7	SUMF2	Sulfatase-modifying factor 2	1.55E-04	7.584	7.79	33950	119	2	8.6
4681	P40261	NNMT	Nicotinamide N-methyltransferase	1.55E-04	12.373	5.56	30011	239	4	17.4
4682	P40261	NNMT	Nicotinamide N-methyltransferase	1.55E-04	8.947	5.56	30011	104	2	7.6
4714	Q14694	UBP10	Ubiquitin carboxyl-terminal hydrolase 10	1.55E-04	7.147	5.19	87707	35	1	1.9
4728	O00299	CLIC1	Chloride intracellular channel protein 1	1.55E-04	11.665	5.09	27248	320	5	24.1
4729	O00299	CLIC1	Chloride intracellular channel protein 1	1.55E-04	10.708	5.09	27248	176	3	17.4
4742	O00299	CLIC1	Chloride intracellular channel protein 1	3.11E-04	6.383	5.09	27248	60	1	5
4754	P08670	VIME	Vimentin	2.95E-03	6.636	5.06	53676	212	4	10.5
5076	C9J035	B3A2	Anion exchange protein 2	1.55E-04	6.587	5.9	137493	41	1	1
5097	P84085	ARF5	ADP-ribosylation factor 5	4.66E-03	7.633	6.3	20631	278	5	34.4
5193	Q16853	AOC3	Membrane primary amine oxidase	3.11E-04	6.428	6.05	85138	37	1	2.5
5197	P23284	PPIB	Peptidyl-prolyl cis-trans isomerase B	3.11E-04	8.197	9.42	23785	427	11	34.7
5198	P23284	PPIB	Peptidyl-prolyl cis-trans isomerase B	1.55E-04	6.554	9.42	23785	202	5	23.6
5578	P14314	GLU2B	Glucosidase 2 subunit beta	6.22E-04	6.496	4.33	60357	205	3	8.1
5668	P27797	CALR	Calreticulin	3.11E-04	6.218	4.29	48283	213	5	8.6
5709	P30101	PDIA3	Protein disulfide-isomerase A3	3.11E-04	9.990	5.98	57146	565	12	22.8
5710	P30101	PDIA3	Protein disulfide-isomerase A3	6.22E-04	8.527	5.98	57146	696	12	26.1
5870	O60583	CCNT2	Cyclin-T2	6.22E-04	7.960	9.04	81492	39	1	1.6
5872	P08670	VIME	Vimentin	6.22E-04	7.763	5.06	53676	952	22	37.1
5928	Q9H3Z4	DNJC5	DnaJ homolog subfamily C member 5	6.22E-04	6.198	4.93	22933	43	1	10.1
5952	Q07065	IF4A1	Eukaryotic initiation factor 4A-I	6.22E-04	15.257		46353		1	2.5
5953	Q07065	IF4A1	Eukaryotic initiation factor 4A-I	3.11E-04	8.525		46353		10	23.4
6062	Q15019	SEPT	Septin-2	6.22E-04	6.664		41689		3	8.6
6126	Q14847	LASP1	LIM and SH3 domain protein 1	1.55E-04	7.205		30097		3	15.3
6127	B4DHY1	HNRH3	Heterogeneous nuclear ribonucleoprotein H3	1.55E-04	6.059		36960		1	3.5
6136	Q5TB53	TM9S3	Transmembrane 9 superfamily member 3	1.09E-03	8.325		68584		1	2

^aSpot numbers refer to those in Figure 1B.

^bAccession numbers of proteins were derived from Swiss-Prot and NCBI nonredundant data bases.

^cObserved isoelectric point and molecular weight calculated according to location on the 2D gel.

^dMascot score for the identified proteins based on the peptide ions score ($p < 0.05$) (<http://www.matrixscience.com>).


Table 2: A list of identified proteins with differential expression between tumor and non-tumor tissues in ES patients.

been investigated. The family protein of CAPZB was implemented in the other types of cancers. For instance, using a proteomics approach, we previously found that macrophage-capping protein (CapG), an actin-capping protein that blocks the barbed ends of F-actin filaments, was associated with resistance of cholangiocellular carcinoma (CCC) to gemcitabine therapy, and using immunohistochemistry we also found that CapG in tumor cells had prognostic utility [23]. Using a proteomics approach, we also found that CapG in tumor tissues was significantly associated with malignant features of gastric cancer [24]. In liver cancer, we reported that CapG was highly expressed in primary tumor tissues with intravascular metastasis [25], and the expression of CapG was confirmed in tumor cells by immunohistochemistry and the functional significances of CapG in liver cancer cells were confirmed by *in vitro* experiments. In breast cancer, higher expression of CapG was observed at the tumor margin, suggesting that that CapG may be involved in tumor cell dissemination and metastasis [26]. These observations suggest that CapG may have diagnostic utility. Recently, van Impe et al. [27] developed a novel nanobody, which is a single-domain antibody, against CapG, and delivered it to breast cancer cells by lentiviral transduction. This resulted in attenuation of cell migration and lung metastasis, and suggested that CapG may have utility as a therapeutic target. As CAPZB has a function similar to that of CapG in

actin organization, we further investigated the expression of CAPZB in tumor tissues of ES.

We confirmed overexpression of CAPZB in ES using Western blotting (Figure 3A). In all eight ES cases, we found that CAPZB was highly expressed in tumor tissues relative to adjacent non-tumor tissues ($p < 0.01$, Figure 3B). These observations were consistent with those of 2D-DIGE, and mass spectrometry supported the correct identification of the protein.

We tried to localize the expression of CAPZB in specific cell types by immunohistochemistry. The immunohistochemical examination is critical in the proteomic study of ES when the tissues are homogenized for protein extraction. The tumor tissues of ES are highly complex, and the proteomic data of the homogenized tissue samples should consist of the mixed proteome data of different cell types. The laser microdissection was often employed to approach the tissue complexity. However, as the conventional laser microdissection for 2D-DIGE does not recover individual single cells [14], it cannot solve the problem of high tissue complexity of ES. To determine the expression of given proteins in tumor cells, immunohistochemistry is mandatory. Without localization data, the further *in vitro* functional studies cannot be significant. We stained the sectioned tissues with the antibody



against CAPZB, which was used for Western blotting. We found that the immunohistochemical staining patterns of CAPZB was not conclusive; the immunohistochemical signals of CAPZB seemed to be non specific and the cellular localization of CAPZB were not consistent among the tissue sections. It may be reasoned by the characters of antibody used in this study; the indication of CAPZB antibody for immunohistochemistry was not guaranteed by antibody supplier. Presently, we could not concluded the cell types where CAPZB localized in tumor tissues of ES. It is worth screening the antibodies which can clearly localize CAPZB in tumor tissues.

Our present study has demonstrated that a proteomics approach can generate intriguing results using tissue samples. At the same time, our study clearly indicated the difficult part of tissue proteomics. Tumor tissues generally contain multiple types of cells, and localization of proteins identified by tissue proteomics should be determined prior to further examinations. However, laser microdissection may not always be a solution for tissue complexity, and immunohistochemical examination to localize the identified proteins does not always work as expected. This inherent drawback of tissue proteomics should be considered when we interpret the proteome data of ES in this study.

Acknowledgements

This work was supported by the National Cancer Center Research Core Facility and the National Cancer Center Research and Development Fund (23-A-7, 23-A-10, and 26-A-9). We appreciate an excellent technical support by Yukiko Nakamura (National Cancer Center Research Institute).

References

- Enzinger FM (1970) Epithelioid sarcoma. A sarcoma simulating a granuloma or a carcinoma. *Cancer* 26: 1029-1041.
- Chase DR, Enzinger FM (1985) Epithelioid sarcoma. Diagnosis, prognostic indicators, and treatment. *Am J Surg Pathol* 9: 241-263.
- Guillou L, Wadden C, Coindre JM, Krausz T, Fletcher CD (1997) "Proximal-

type" epithelioid sarcoma, a distinctive aggressive neoplasm showing rhabdoid features. *Clinicopathologic, immunohistochemical, and ultrastructural study of a series.* *Am J Surg Pathol* 21: 130-146.

- Chbani L, Guillou L, Terrier P, Decouvelaere AV, Grégoire F, et al. (2009) Epithelioid sarcoma: a clinicopathologic and immunohistochemical analysis of 106 cases from the French sarcoma group. *Am J Clin Pathol* 131: 222-227.
- Fisher C (2006) Epithelioid sarcoma of Enzinger. *Adv Anat Pathol* 13: 114-121.
- Evans HL, Baer SC (1993) Epithelioid sarcoma: a clinicopathologic and prognostic study of 26 cases. *Semin Diagn Pathol* 10: 286-291.
- Baratti D, Pennacchioli E, Casali PG, Bertulli R, Lozza L, et al. (2007) Epithelioid sarcoma: prognostic factors and survival in a series of patients treated at a single institution. *Ann Surg Oncol* 14: 3542-3551.
- Modena P, Lualdi E, Facchinetti F, Galli L, Teixeira MR, et al. (2005) SMARCB1/INI1 tumor suppressor gene is frequently inactivated in epithelioid sarcomas. *Cancer Res* 65: 4012-4019.
- Hornick JL, Dal Cin P, Fletcher CD (2009) Loss of INI1 expression is characteristic of both conventional and proximal-type epithelioid sarcoma. *Am J Surg Pathol* 33: 542-550.
- Brenca M, Rossi S, Lorenzetto E, Piccinin E, Piccinin S, et al. (2013) SMARCB1/INI1 genetic inactivation is responsible for tumorigenic properties of epithelioid sarcoma cell line VAESBJ. *Mol Cancer Ther* 12: 1060-1072.
- Papp G, Krausz T, Stricker TP, Szendroi M, Sapi Z (2014) SMARCB1 expression in epithelioid sarcoma is regulated by miR-206, miR-38, and miR-671-5p on Both mRNA and protein levels. *Genes Chromosomes Cancer* 53: 168-176.
- Weber A, Engers R, Nockemann S, Gohr LL, Zur Hausen A, et al. (2001) Differentially expressed genes in association with in vitro invasiveness of human epithelioid sarcoma. *Mol Pathol* 54: 324-330.
- Lushnikova T, Knuutila S, Miettinen M (2000) DNA copy number changes in epithelioid sarcoma and its variants: a comparative genomic hybridization study. *Mod Pathol* 13: 1092-1096.
- Kondo T, Hirohashi S (2007) Application of highly sensitive fluorescent dyes (CyDye DIGE Fluor saturation dyes) to laser microdissection and two-dimensional difference gel electrophoresis (2D-DIGE) for cancer proteomics. *Nat Protoc* 1: 2940-2956.
- Unlü M, Morgan ME, Minden JS (1997) Difference gel electrophoresis: a single gel method for detecting changes in protein extracts. *Electrophoresis* 18: 2071-2077.
- Shaw J, Rowlinson R, Nickson J, Stone T, Sweet A, et al. (2003) Evaluation of saturation labelling two-dimensional difference gel electrophoresis fluorescent dyes. *Proteomics* 3: 1181-1195.
- Righetti PG (1990) Immobilized pH gradients: theory and methodology, Elsevier.
- Romero-Calvo I, Ocón B, Martínez-Moya P, Suárez MD, Zarzuelo A, et al. (2010) Reversible Ponceau staining as a loading control alternative to actin in Western blots. *Anal Biochem* 401: 318-320.
- Klein D, Kern RM, Sokol RZ (1995) A method for quantification and correction of proteins after transfer to immobilization membranes. *Biochem Mol Biol Int* 36: 59-66.
- Barron-Casella EA, Torres MA, Scherer SW, Heng HH, Tsui LC, et al. (1995) Sequence analysis and chromosomal localization of human Cap Z. Conserved residues within the actin-binding domain may link Cap Z to gelsolin/severin and profilin protein families. *J Biol Chem* 270: 21472-21479.
- Bai SW, Herrera-Abreu MT, Rohn JL, Racine V, Tajadura V, et al. (2011) Identification and characterization of a set of conserved and new regulators of cytoskeletal organization, cell morphology and migration. *BMC Biol* 9: 54.
- Kamo M, Sato N (2006) Proteins profiling of human salivary intercalated duct cell line by proteomics. *Japanese Journal of Tissue Culture Dental Research* 15: 11-28.
- Morofuji N, Ojima H, Onaya H, Okusaka T, Shimada K, et al. (2012) Macrophage-capping protein as a tissue biomarker for prediction of response to gemcitabine treatment and prognosis in cholangiocarcinoma. *J Proteomics* 75: 1577-1589.
- Ichikawa H, Kanda T, Kosugi S, Kawachi Y, Sasaki H, et al. (2013) Laser

- microdissection and two-dimensional difference gel electrophoresis reveal the role of a novel macrophage-capping protein in lymph node metastasis in gastric cancer. *J Proteome Res* 12: 3780-3791.
25. Kimura K, Ojima H, Kubota D, Sakamoto M, Nakamura Y, et al. (2013) Proteomic identification of the macrophage-capping protein as a protein contributing to the malignant features of hepatocellular carcinoma. *J Proteomics* 78: 362-373.
26. Kang S, Kim MJ, An H, Kim BG, Choi YP, et al. (2010) Proteomic molecular portrait of interface zone in breast cancer. *J Proteome Res* 9: 5638-5645.
27. Van Impe K, Bethuyne J, Cool S, Impens F, Ruano-Gallego D, et al. (2013) A nanobody targeting the F-actin capping protein CapG restrains breast cancer metastasis. *Breast Cancer Res* 15: R116.